Eisai Inc (Teaneck, NJ) recentlyannounced that it has assumed US distributionresponsibilities for Aciphex(rabeprazole sodium) from JanssenPharmaceutica Inc affiliate JOMPharmaceutical Services. Eisai andJanssen will continue to co-promoteAciphex, a proton pump inhibitor prescribedfor gastro-esophageal reflux disease(GERD). Eisai is fulfilling purchaseorders for Aciphex from a contract distributioncenter in Memphis, Tenn.The productis indicated for the treatment of symptomaticGERD, healing of erosive GERD,and maintenance of healed erosiveGERD. Aciphex also is approved as partof the first 7-day treatment forHelicobacter pylori infections, the singlemost common cause of peptic ulcers. Formore information, visit www.aciphex.com,or call 888-4ACIPHEX (888-422-4743).